At an OMMA Executive Advisory Council meeting, patients, growers and industry representatives used a new public comment period to press for transparency, raise safety concerns about unregulated products and urge more industry representation; council and agency staff reported progress on lab accreditation and IT systems and discussed several pending legislative bills including proposed potency limits.